✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
BPC-157 has been hyped for tendons, joints, and gym recovery — but its actual name (Body Protection Compound 157) and entire research history start in the gut. The peptide was isolated by Sikiric’s group from a protective fragment of human gastric juice in the early 1990s, and almost every animal model that built its reputation looks at stomach ulcers, NSAID damage, colitis, or fistula healing. If you came to BPC-157 from a tendon injury that’s fashionable. If you came from inflammatory bowel disease, leaky-gut hypotheses, or chronic NSAID-related stomach pain, you’re closer to what the original science actually measured.
Quick Answer — BPC-157 for gut health in one paragraph
BPC-157 is a synthetic pentadecapeptide derived from a gastric juice fragment. In rats it accelerates healing in nearly every model of GI injury tested — alcohol ulcer, NSAID-induced stomach lesions, TNBS and DSS colitis, esophagitis, and surgically induced intestinal fistulae — at oral or systemic doses around 10 µg/kg. Human evidence is thin: one 2012 ulcerative colitis pilot and many anecdotal reports. Oral BPC-157 (capsule or sublingual) has decent face validity for upper- and lower-GI work because the peptide is acid-stable and the GI lining is what it’s been hitting in every rat study for thirty years. It is not a substitute for mesalamine, biologics, or PPI therapy, but a meaningful adjunct that more clinicians should be tracking.
What BPC-157 actually is — and why “gut” was always the obvious target
BPC stands for Body Protection Compound. The original 1991-1993 Sikiric papers describe a protective protein fragment recovered from human gastric juice that prevented and accelerated healing of chemically induced ulcers in rats. The active 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) became the synthetic peptide now sold for research as BPC-157 — sometimes labelled PL-14736, the developmental code used during the Phase II ulcerative colitis trial that Pliva ran in 2012.
That history matters because almost every other claim made about BPC-157 — for tendon, ligament, neuropathic pain, brain injury, cardiac arrhythmia — is a downstream extrapolation. The gut data is the upstream reservoir.
The gastrointestinal evidence base, at a glance
The table below summarises the principal animal models where BPC-157 has been measured against gut injury. Doses are scaled from published rat-study protocols; µg/kg refers to the rodent dose and should be considered translational shorthand, not a human prescription.
| Model | Injury induced by | Result with BPC-157 | Lead investigators |
|---|---|---|---|
| Gastric ulcer | Ethanol, cysteamine, stress | Lesion area ↓60-90% at 10 µg/kg PO or IP | Sikiric 1993-2010 |
| NSAID-induced damage | Indomethacin, aspirin, diclofenac | Protected stomach and small intestine; reduced bleeding | Sikiric, Brcic, Klicek |
| Ulcerative colitis (rat) | TNBS, DSS, acetic acid | Reduced colitis macroscopic scores and myeloperoxidase | Veljaca, Sikiric |
| UC (human Phase II) | Active mild-to-moderate UC | PL-14736 trial completed; trended toward improvement, never reached Phase III | Pliva / Sikiric 2012 |
| Esophagitis / GERD model | Acid reflux, sphincter incompetence | Lower esophageal sphincter pressure restored; mucosa healed | Petek, Sikiric |
| Intestinal fistula | Surgical creation (rectovaginal, colocutaneous) | Accelerated closure of established fistulae | Skorjanec, Sikiric |
| Short bowel syndrome (rat) | Massive small-bowel resection | Mucosal adaptation, villus height ↑ | Sever, Sikiric |
| Liver / portal pressure | Bile duct ligation, ischaemia | Reduced portal hypertension; protective on hepatocytes | Sikiric, Drmic |
The takeaway is not that BPC-157 cures inflammatory bowel disease in humans — it doesn’t. The takeaway is that almost every endpoint a gastroenterologist cares about (mucosal healing, lesion area, MPO, sphincter tone, fistula closure) moves in the right direction in animal models with broad consistency across labs.
Research Spotlight — the 2012 ulcerative colitis trial
Pliva (now Teva) ran a Phase II trial of PL-14736 — pharmaceutical-grade BPC-157 — in mild-to-moderate ulcerative colitis. The trial completed and reported safety data and trends toward clinical improvement, but the asset was not advanced. There is no Phase III data, no marketed pharmaceutical, and no regulatory approval. The peptide remains, formally, a research compound. If you are reading marketing copy that calls BPC-157 “clinically proven for IBD,” it is overselling — but if you are reading copy that calls it “purely anecdotal,” it is also underselling: a Phase II completion is more than nothing.
Oral vs subcutaneous for gut work — the format question
For most BPC-157 use cases the oral-vs-injection debate is unresolved because the peptide’s plasma half-life and tissue distribution after oral dosing are still poorly characterised in humans. For the gut specifically, the case for oral is much stronger — for the same reason it’s stronger for a topical eye drop than for an oral one: the lining you are trying to heal is exactly where the drug is sitting.
- Oral capsule (lyophilised peptide in vegetable cap): the peptide contacts the upper GI mucosa directly. Acid-stability data from the Sikiric group suggests BPC-157 survives gastric pH well — unusual for a 15-mer peptide. Most popular for ulcer, gastritis, and IBD research protocols.
- Sublingual liquid: bypasses some first-pass acid but defeats the purpose if your target tissue is gastric or colonic. Useful for systemic effects (tendon, joint, brain).
- Subcutaneous injection (SC): reliable systemic exposure but the peptide must redistribute back to gut tissue. Preferred for fistula work where the lesion is deep, and for short-bowel research protocols.
- Rectal suspension: rarely used outside study protocols, but logical for distal UC and proctitis given the topical-to-mucosa logic.
Practical convention in the research community: oral for upper GI (gastritis, NSAID protection, reflux), SC plus oral for IBD and fistula, and SC alone for everything else. We’ve covered the full bioavailability comparison in BPC-157 Oral vs Injectable: Bioavailability, Formats & How to Choose.
Dosing conventions for gut protocols
The doses below are common in the research community and mirror the µg/kg scaling used in Sikiric’s protocols. They are not medical advice and BPC-157 is not approved as a medicine in any jurisdiction.
| Use case | Typical research dose | Route | Cycle length |
|---|---|---|---|
| Gastritis / NSAID protection | 250-500 µg/day | Oral, divided BID | 4-6 weeks |
| Mild UC / colitis adjunct | 500 µg/day | Oral + SC split | 6-8 weeks |
| Leaky-gut / functional dyspepsia | 250 µg/day | Oral | 4 weeks |
| Post-surgical fistula / anastomosis | 500-750 µg/day | SC + oral | 8-12 weeks |
| Reflux / esophagitis | 250 µg/day | Oral or sublingual | 3-4 weeks |
Practitioners running structured protocols typically split doses morning and evening, run for 4-8 weeks, and reassess. For the reconstitution math (BAC water volumes, syringe markings, capsule potency) see BPC-157 Reconstitution & Dosing Calculator and BAC Water (Bacteriostatic Water) reconstitution guide.
BPC-157 for inflammatory bowel disease — what the data does and doesn’t say
Ulcerative colitis and Crohn’s disease are not interchangeable, and BPC-157’s research record favours UC over Crohn’s.
- Ulcerative colitis — mucosal disease confined to the colon; the rat TNBS and DSS models are well-characterised; the Phase II human trial targeted UC specifically. Reasonable case for adjunct use alongside conventional 5-ASA / mesalamine therapy.
- Crohn’s disease — transmural inflammation, often with fistulae and strictures; relevant rat data is mostly the fistula-healing line. Less direct evidence; biologic therapy remains the standard for moderate-to-severe disease.
BPC-157 is not a substitute for mesalamine, immunomodulators, or biologic therapy in active IBD. Patients have reported using it alongside conventional therapy with subjective improvement in fistula healing and post-flare recovery — but the controlled human evidence is one Phase II trial. Anyone considering this should do so with their gastroenterologist informed and conventional therapy continued. Our wider IBS/IBD landscape is covered in Best IBS & IBD Treatments: 7 Evidence-Backed Picks for Bowel Disease.
Leaky gut and intestinal permeability — the uncomfortable section
“Leaky gut” is a popular wellness term and a contested medical one. Intestinal permeability is real and measurable (zonulin, lactulose/mannitol ratio), and it is elevated in coeliac disease, IBD, and a subset of IBS patients. Leaky gut as a stand-alone diagnosis is not recognised by mainstream gastroenterology, and most of the popular protocols (bone broth, glutamine, slippery elm, BPC-157) sit on indirect evidence.
The honest case for BPC-157 in this space: it accelerates mucosal healing in rodent injury models, increases mucus-layer integrity, and modulates the gut-vagus-brain axis. The honest limit: there is no controlled human trial showing it reduces serum zonulin or lactulose/mannitol ratios. People who report improvement in functional dyspepsia, post-antibiotic gut symptoms, or NSAID-related gastritis appear to do reasonably well; people expecting it to fix vague unrelated symptoms (skin, mood, fatigue) reliably are working off a marketing claim, not an evidence base.
BPC-157 against NSAID damage — the strongest non-IBD case
For chronic NSAID users (osteoarthritis, ankylosing spondylitis, chronic pain) the BPC-157 NSAID-protection literature is among the most robust in the field. Indomethacin, aspirin, and diclofenac in rats reliably produce gastric and small-bowel lesions; BPC-157 co-administration reliably attenuates them. The mechanism appears to involve nitric oxide modulation, growth-factor expression (VEGF, EGFR), and dopamine-system stabilisation — although a clean mechanistic story is still emerging.
For someone taking daily diclofenac for osteoarthritis who cannot tolerate a PPI long-term, adding a 4-6 week BPC-157 cycle has a plausible biological rationale. It is not a substitute for the PPI when one is clinically indicated, and it does not replace the foundational risk discussion (PPI titration, COX-2 selection, lowest effective dose). For the prescription PPI alternatives landscape see Voquezna vs Pantoprazole: PCAB vs PPI Comparison.
What BPC-157 cannot do for gut health
Honest limits
- It does not replace mesalamine, biologics, or steroid therapy in moderate-to-severe IBD.
- It does not have a Phase III trial behind it for any indication, anywhere.
- It does not address bacterial overgrowth, parasitic infection, or coeliac disease — those need targeted therapy (rifaximin, antiparasitics, gluten elimination).
- It does not reverse advanced fibrostenotic Crohn’s strictures; once tissue is scarred the peptide does not have a meaningful undo lever.
- It does not replace H. pylori eradication when an active infection is present.
Side effects and the cancer question
BPC-157’s safety record across published studies is reassuring — it is one of the better-tolerated experimental peptides — but it is not zero-risk. Reported side effects from human anecdotal use include mild injection-site reactions (for SC routes), light-headedness in the first few doses, and occasional GI cramping at higher oral doses.
The cancer question deserves its own paragraph. Because BPC-157 modulates growth factors (VEGF, EGFR, FGF) and accelerates tissue repair, it is fair to ask whether it could theoretically support tumour growth as well as healing. The animal evidence is mixed and short-duration; there is no human carcinogenicity data and no long-term safety database. People with a personal history of cancer, particularly hormone-sensitive or VEGF-driven cancers, should not casually self-administer BPC-157 without specialist input. We covered the full risk profile in BPC-157 Side Effects: Complete Safety Profile, Real-World Reports & Risk Factors and the parallel question for the sister peptide in TB-500 Side Effects: The Cancer-Risk Question & Real-World Reports.
Stacks: BPC-157 + KPV + TB-500 for gut work
Two peptide stacking combinations come up consistently in gut-focused research protocols:
- BPC-157 + KPV — the alpha-MSH-derived tripeptide KPV (Lys-Pro-Val) has its own anti-inflammatory and IBD-model literature. Where BPC-157 drives mucosal healing, KPV dampens the NF-κB inflammatory cascade. The two are mechanistically complementary. Compared head-to-head in our BPC-157 vs KPV breakdown.
- BPC-157 + TB-500 (Thymosin beta-4) — TB-500’s angiogenesis and cell-migration profile makes the stack popular for post-surgical anastomosis healing and fistula closure. The combined blend is sold as a BPC-157 + TB-500 blend or as part of the broader Peptide Healing Stack with BAC water included. See Peptide Blends Explained for the trade-offs of pre-mixed blends vs single-peptide reconstitution.
Sourcing research-grade BPC-157
BPC-157 is a research peptide, not an approved medicine. Quality matters more here than for many pharmaceuticals because there is no FDA-mandated purity standard — what you get depends entirely on the supplier’s third-party HPLC and mass-spec verification.
Practical sourcing checklist:
- HPLC purity ≥ 98%, ideally ≥ 99%
- Mass spectrometry sequence confirmation on every batch — not just an HPLC chromatogram
- Lyophilised peptide in a sealed vial, not pre-reconstituted
- Cold-chain or temperature-stable shipping
- Certificate of Analysis available per batch — see How to Read a Peptide Certificate of Analysis
Our research-grade BPC-157 vial, the BPC-157 + TB-500 blend, and the complete Peptide Healing Stack with BAC water all ship with HPLC and mass-spec verification. Worldwide Shipping available for research-use buyers.
Who is this for?
BPC-157 for gut research makes the most sense for: chronic NSAID users with documented gastropathy, mild ulcerative colitis patients looking for an adjunct alongside mesalamine, post-surgical anastomosis or fistula recovery, functional dyspepsia with mucosal-injury features, and reflux-esophagitis patients who are PPI-resistant or seeking PPI-sparing approaches. It is not for: severe IBD requiring biologics, active H. pylori infection (treat the bug first), or hormone-sensitive cancer patients without specialist oversight.
Frequently Asked Questions
Was BPC-157 really discovered in human gastric juice?
Yes. The Sikiric group at the University of Zagreb isolated a protective protein fragment from human gastric juice in the early 1990s; the 15-amino-acid synthetic sequence now sold as BPC-157 is derived from that natural fragment.
Does oral BPC-157 actually survive stomach acid?
Published stability data from the Sikiric group indicates BPC-157 is unusually acid-stable for a 15-mer peptide — likely because of the proline-rich middle sequence that resists protease cleavage. Oral capsule and sublingual liquid formats are widely used in research protocols specifically for upper-GI work.
Is BPC-157 approved for ulcerative colitis or IBD?
No. Pliva ran a completed Phase II trial of pharmaceutical-grade BPC-157 (coded PL-14736) in mild-to-moderate ulcerative colitis around 2012. The trial reported reasonable safety and trends toward improvement but was not advanced to Phase III. There is no marketed pharmaceutical and no regulatory approval anywhere.
Can I take BPC-157 with mesalamine or biologics?
There is no published interaction data either way. Patients on conventional IBD therapy who add BPC-157 should keep their gastroenterologist informed and continue first-line therapy. BPC-157 is positioned as an adjunct, never a replacement, for proven IBD treatments.
How long does it take to feel a gut-symptom change?
Self-reported timelines vary but most users describe noticing reflux, gastritis, or functional dyspepsia changes within 7-14 days. IBD-style improvements are slower and more variable, often requiring 4-8 weeks at consistent dosing. There is no validated time-to-response figure from controlled human research.
Should I take it on an empty stomach or with food?
For upper-GI use cases the convention is on an empty stomach (10-20 minutes before food) to maximise mucosal contact time. For systemic effects timing matters less. There is no robust pharmacokinetic study in humans to settle this definitively.
Can BPC-157 help with H. pylori?
It does not eradicate the bacterium. If you have an active H. pylori infection, that needs to be treated with the appropriate antibiotic triple or quadruple therapy first. BPC-157 may help mucosal recovery after eradication, but it does not replace antibacterial therapy.
Is BPC-157 safe to use long-term?
There is no long-term human safety database. Short-term human use (weeks to a few months) is well-tolerated in the available reports. Practitioners typically run 4-8 week cycles followed by a break rather than continuous use — see our Peptide Cycling Protocols Explained for the general framework.
What’s the difference between BPC-157 and the “stable” or “arginate” form?
“BPC-157 arginate” and similar marketing terms describe salt forms with claimed stability advantages. The bioactive peptide is the same 15-amino-acid sequence in every case. Salt form matters for storage and shipping more than for biological activity.
Can I take BPC-157 if I have a history of cancer?
This deserves an honest answer: BPC-157 modulates growth factors involved in tissue repair, and there is no long-term human cancer-risk database. People with a personal history of cancer — particularly hormone-sensitive or VEGF-driven cancers — should not casually self-administer BPC-157 without specialist input. The risk-benefit calculation is genuinely uncertain here, not safely dismissable in either direction.
The bottom line
BPC-157 was always a gut peptide before it was a tendon peptide. Three decades of Sikiric’s animal work, a completed (but unfinalised) Phase II UC trial, and a steady drip of human anecdote support its place as a credible adjunct for mucosal-injury research — gastritis, NSAID damage, mild UC, post-surgical fistula, reflux. It is not a cure for IBD, not a substitute for PPI when one is indicated, and not a casual supplement for people with cancer histories. Used inside those guardrails, at standard research doses, in oral form for upper-GI work and split oral-plus-SC for colitis or fistula work, it is one of the more biologically rational peptides on offer.
For the foundational pillar see BPC-157 Peptide: Healing, Dosage & Safety Guide. For practical setup: reconstitution and dosing, lyophilised peptide reconstitution math, and the broader peptide research catalogue.
What you get with MedsBase:
- Research-grade peptides with HPLC ≥ 98% purity and mass-spec sequence confirmation
- Certificate of Analysis available per batch
- Discreet packaging in plain envelope
- Worldwide Shipping with Reshipment Assurance
📦 Reshipment Assurance: if your order has not arrived within 20 business days from dispatch, we reship at our cost. See full terms in our Reshipment Assurance Policy.
Medical disclaimer: BPC-157 is a research peptide and is not approved as a medicine in any jurisdiction. The information above is intended for research and educational purposes; it is not medical advice and is not a substitute for consultation with a qualified clinician. People with active gastrointestinal disease, cancer history, or who are pregnant or breastfeeding should not self-administer research peptides without specialist input.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.